Vontobel Holding Ltd. Takes Position in Replimune Group, Inc. (NASDAQ:REPL)

Vontobel Holding Ltd. purchased a new stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 305,412 shares of the company's stock, valued at approximately $2,575,000. Vontobel Holding Ltd. owned 0.52% of Replimune Group at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Swiss National Bank grew its holdings in shares of Replimune Group by 8.2% during the 1st quarter. Swiss National Bank now owns 49,900 shares of the company's stock worth $847,000 after purchasing an additional 3,800 shares in the last quarter. MetLife Investment Management LLC grew its stake in Replimune Group by 54.2% during the first quarter. MetLife Investment Management LLC now owns 15,209 shares of the company's stock worth $258,000 after buying an additional 5,344 shares in the last quarter. Rhumbline Advisers increased its holdings in Replimune Group by 5.2% in the 1st quarter. Rhumbline Advisers now owns 32,643 shares of the company's stock valued at $554,000 after buying an additional 1,616 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Replimune Group by 48.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 344,397 shares of the company's stock valued at $5,848,000 after buying an additional 111,920 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Replimune Group by 5.3% in the 1st quarter. Vanguard Group Inc. now owns 1,625,758 shares of the company's stock valued at $27,606,000 after buying an additional 81,845 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company's stock.

Replimune Group Price Performance

Shares of NASDAQ REPL traded down $0.52 during trading hours on Friday, hitting $6.45. 866,616 shares of the stock were exchanged, compared to its average volume of 1,354,570. The company's fifty day simple moving average is $7.97 and its two-hundred day simple moving average is $9.60. The company has a market cap of $395.97 million, a PE ratio of -2.04 and a beta of 1.21. The company has a debt-to-equity ratio of 0.16, a quick ratio of 12.40 and a current ratio of 12.40. Replimune Group, Inc. has a 1-year low of $5.89 and a 1-year high of $24.81.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its earnings results on Thursday, February 8th. The company reported ($0.77) earnings per share for the quarter, beating analysts' consensus estimates of ($0.89) by $0.12. On average, sell-side analysts predict that Replimune Group, Inc. will post -3.28 EPS for the current year.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.